- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
DR5 Polyclonal Antibody / CD262 Rabbit Polyclonal Antibody targets death receptor 5 (DR5), a transmembrane signaling protein encoded by the TNFRSF10B gene. Also known as CD262, TRAIL receptor 2 (TRAILR2), and KILLER, DR5 belongs to the tumor necrosis factor receptor superfamily and regulates programmed cell death. It binds tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), encoded by TNFSF10, and initiates signaling through the extrinsic apoptotic pathway. Unlike TRAIL decoy receptors, DR5 contains a functional intracellular death domain capable of recruiting proteins required for caspase activation.
DR5 contains extracellular cysteine-rich domains, a transmembrane segment, and a cytoplasmic death domain. Binding of TRAIL promotes receptor clustering and assembly of the death-inducing signaling complex (DISC). This complex recruits the adaptor protein FADD and initiator procaspases, particularly procaspase-8, leading to proteolytic activation of downstream caspases. Activated caspase-8 can directly activate executioner caspases or cleave BID to engage mitochondrial apoptotic signaling. These events contribute to the coordinated elimination of damaged, infected, or otherwise abnormal cells.
DR5 signaling is regulated by receptor expression, intracellular trafficking, glycosylation, and the availability of pro-apoptotic and anti-apoptotic proteins. TNFRSF10B transcription can increase in response to cellular stress through pathways involving p53 and other transcription factors. Depending on cellular context, TRAIL receptor activation can also stimulate non-apoptotic signaling pathways, including NF-kappaB and MAP kinase cascades. These responses may influence inflammation, cellular migration, and survival rather than apoptosis. The balance between these signaling outcomes depends on receptor organization and the molecular environment within individual cells.
DR5 is an important focus of cancer research because TRAIL-mediated apoptosis can contribute to the elimination of malignant cells. However, tumor cells may develop resistance through altered death receptor expression, impaired caspase activation, or increased anti-apoptotic signaling. Therapeutic approaches targeting DR5 have been investigated as strategies for promoting tumor-cell death, although receptor activation does not uniformly produce apoptosis across cancer types. DR5 Polyclonal Antibody supports investigations of TNFRSF10B expression, death receptor regulation, apoptotic signaling, and mechanisms associated with cancer-cell survival.
For an alternative monoclonal antibody targeting this apoptosis-regulating receptor, see our DR5 Antibody DR5/3381, validated for immunohistochemistry and supported by human protein microarray specificity analysis.
Optimal dilution of the DR5 Polyclonal Antibody / CD262 Rabbit Polyclonal Antibody should be determined by the researcher.
Amino acids K233-S440 from the human protein were used as the immunogen for the DR5 antibody.
After reconstitution, the DR5 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.
Death receptor 5 antibody, TRAIL receptor 2 antibody, TRAILR2 antibody, TRAIL R2 antibody, CD262 antibody, KILLER antibody, TNF receptor superfamily member 10B antibody, Tumor necrosis factor receptor superfamily member 10B antibody, TRICK2 antibody, TRICK2A antibody, TRICK2B antibody, TRICKB antibody, ZTNFR9 antibody, KILLER/DR5 antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.